183 related articles for article (PubMed ID: 18310141)
1. Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid.
Hyland K
Clin Chem; 2008 Apr; 54(4):633-41. PubMed ID: 18310141
[TBL] [Abstract][Full Text] [Related]
2. Ventricular cerebrospinal fluid monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases.
Wester P; Bergström U; Eriksson A; Gezelius C; Hardy J; Winblad B
J Neurochem; 1990 Apr; 54(4):1148-56. PubMed ID: 1968956
[TBL] [Abstract][Full Text] [Related]
3. Presentation, diagnosis, and treatment of the disorders of monoamine neurotransmitter metabolism.
Hyland K
Semin Perinatol; 1999 Apr; 23(2):194-203. PubMed ID: 10331470
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood gene expression profiles linked to monoamine metabolite levels in cerebrospinal fluid.
Luykx JJ; Olde Loohuis LM; Neeleman M; Strengman E; Bakker SC; Lentjes E; Borgdorff P; van Dongen EP; Bruins P; Kahn RS; Horvath S; de Jong S; Ophoff RA
Transl Psychiatry; 2016 Dec; 6(12):e983. PubMed ID: 27959337
[TBL] [Abstract][Full Text] [Related]
5. Clinical Use of CSF Neurotransmitters.
Rodan LH; Gibson KM; Pearl PL
Pediatr Neurol; 2015 Oct; 53(4):277-86. PubMed ID: 26194033
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid monoamine precursors and metabolites in human neonates following in utero cocaine exposure: a preliminary study.
Needlman R; Zuckerman B; Anderson GM; Mirochnick M; Cohen DJ
Pediatrics; 1993 Jul; 92(1):55-60. PubMed ID: 8516085
[TBL] [Abstract][Full Text] [Related]
7. Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP-432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects.
Sramek JJ; Hardy LW; Bieck P; Zamora C; Versavel M; Kharidia J; Grinnell T; Chen YL; Sullivan M; Ding H; Cutler NR
CNS Neurosci Ther; 2016 May; 22(5):404-12. PubMed ID: 26849844
[TBL] [Abstract][Full Text] [Related]
8. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes.
Kurian MA; Gissen P; Smith M; Heales S; Clayton PT
Lancet Neurol; 2011 Aug; 10(8):721-33. PubMed ID: 21777827
[TBL] [Abstract][Full Text] [Related]
9. No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals.
Hjärpe J; Söderman E; Andreou D; Sedvall GC; Agartz I; Jönsson EG
Psychiatry Res; 2018 May; 263():30-34. PubMed ID: 29482043
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous quantification of monoamine neurotransmitters and their biogenic metabolites intracellularly and extracellularly in primary neuronal cell cultures and in sub-regions of guinea pig brain.
Schou-Pedersen AMV; Hansen SN; Tveden-Nyborg P; Lykkesfeldt J
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():222-230. PubMed ID: 27379407
[TBL] [Abstract][Full Text] [Related]
11. Monoamine neurotransmitters and metabolites in the cerebrospinal fluid following perinatal asphyxia.
Blennow M; Zeman J; Dahlin I; Lagercrantz H
Biol Neonate; 1995; 67(6):407-13. PubMed ID: 7578624
[TBL] [Abstract][Full Text] [Related]
12. Qualitative and quantitative high performance liquid chromatographic analysis of monoamine neurotransmitters and metabolites in cerebrospinal fluid and brain tissue using reductive electrochemical detection.
Schmidt D; Roznoski M; Ebert MH
Biomed Chromatogr; 1990 Sep; 4(5):215-20. PubMed ID: 1980626
[TBL] [Abstract][Full Text] [Related]
13. Developmental changes in cerebrospinal fluid concentrations of monoamine-related substances revealed with a Coulochem electrode array system.
Takeuchi Y; Matsushita H; Sakai H; Kawano H; Yoshimoto K; Sawada T
J Child Neurol; 2000 Apr; 15(4):267-70. PubMed ID: 10805197
[TBL] [Abstract][Full Text] [Related]
14. In situ imaging of monoamine localization and dynamics.
Sugiyama E; Skelly AN; Suematsu M; Sugiura Y
Pharmacol Ther; 2020 Apr; 208():107478. PubMed ID: 31931099
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans.
Kim H; Lee H; Rowan J; Brahim J; Dionne RA
Mol Pain; 2006 Jul; 2():24. PubMed ID: 16848906
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders.
Ng J; Heales SJ; Kurian MA
Paediatr Drugs; 2014 Aug; 16(4):275-91. PubMed ID: 25011953
[TBL] [Abstract][Full Text] [Related]
17. Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity?
Scheinin M
Med Biol; 1985; 63(1):1-17. PubMed ID: 2582215
[TBL] [Abstract][Full Text] [Related]
18. [Alteration of neurotransmitters in the cerebrospinal fluid in SHRSP rats due to long-term administration of clonidine].
Iwasaki E; Takasugi Y; Koga Y
Masui; 2006 Mar; 55(3):330-7. PubMed ID: 16541782
[TBL] [Abstract][Full Text] [Related]
19. Monoamine Neurotransmitter Metabolite Concentration as a Marker of Cerebrospinal Fluid Volume Changes.
Maraković J; Vukić M; Radoš M; Chudy D; Klarica M; Orešković D
Acta Neurochir Suppl; 2016; 122():283-6. PubMed ID: 27165922
[TBL] [Abstract][Full Text] [Related]
20. Monoamine neurotransmitter disorders--clinical advances and future perspectives.
Ng J; Papandreou A; Heales SJ; Kurian MA
Nat Rev Neurol; 2015 Oct; 11(10):567-84. PubMed ID: 26392380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
